| GC30276-5mg |
|
863598-09-8 |
Casein Kinase II Inhibitor IV
|
0 |
C24H23N5O3 |
|
|
|
| GC30276-10mM(1mLinDMSO) |
|
863598-09-8 |
Casein Kinase II Inhibitor IV
|
0 |
C24H23N5O3 |
|
|
|
| GC30274-1g |
|
20666-12-0 |
|
0 |
C8H7N3NaO2+ |
|
|
|
| GC30273-20mg |
|
960151-65-9 |
Tedatioxetine hydrobromide (Lu AA 24530 hydrobromide)
|
0 |
C18H22BrNS |
|
|
|
| GC30273-10mg |
|
960151-65-9 |
Tedatioxetine hydrobromide (Lu AA 24530 hydrobromide)
|
0 |
C18H22BrNS |
|
|
|
| GC30273-5mg |
|
960151-65-9 |
Tedatioxetine hydrobromide (Lu AA 24530 hydrobromide)
|
0 |
C18H22BrNS |
|
|
|
| GC30273-1mg |
|
960151-65-9 |
Tedatioxetine hydrobromide (Lu AA 24530 hydrobromide)
|
0 |
C18H22BrNS |
|
|
|
| GC30272-10mg |
|
1392493-34-3 |
Cyantraniliprole D3 (HGW-86 D3)
|
0 |
C19H11D3BrClN6O2 |
|
|
|
| GC30272-5mg |
|
1392493-34-3 |
Cyantraniliprole D3 (HGW-86 D3)
|
0 |
C19H11D3BrClN6O2 |
|
|
|
| GC30272-1mg |
|
1392493-34-3 |
Cyantraniliprole D3 (HGW-86 D3)
|
0 |
C19H11D3BrClN6O2 |
|
|
|
| GC30271-100mg |
|
63699-78-5 |
|
0 |
C12H16N4O7 |
|
|
|
| GC30271-10mM(1mLinWater) |
|
63699-78-5 |
|
0 |
C12H16N4O7 |
|
|
|
| GC30270-1mg |
|
85138-49-4 |
BCECF (2′,7′-Bis(2-carboxyethyl)-5(6)-carboxyfluorescein)
|
0 |
C27H20O11 |
|
|
|
| GC30269-500mg |
|
886-50-0 |
|
0 |
C10H19N5S |
|
|
|
| GC30269-10mM(1mLinDMSO) |
|
886-50-0 |
|
0 |
C10H19N5S |
|
|
|
| GC30268-5mg |
|
34620-76-3 |
Maltopentaose (Maltopentose)
|
0 |
C30H52O26 |
|
|
|
| GC30268-10mM(1mLinDMSO) |
|
34620-76-3 |
Maltopentaose (Maltopentose)
|
0 |
C30H52O26 |
|
|
|
| GC30267-25mg |
|
85371-64-8 |
|
0 |
C13H21N5O |
|
|
|
| GC30267-10mg |
|
85371-64-8 |
|
0 |
C13H21N5O |
|
|
|
| GC30267-5mg |
|
85371-64-8 |
|
0 |
C13H21N5O |
|
|
|
